| Q43477578 | Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients |
| Q36768605 | Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use |
| Q38221083 | Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients |
| Q34008593 | Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia |
| Q38008448 | Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. |
| Q38340201 | How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation? |
| Q38206275 | Monoclonal antibodies as therapeutics in human malignancies |
| Q39034623 | Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia |
| Q35714606 | Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis |
| Q33394308 | Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients |
| Q35908498 | Therapeutic antibodies against cancer |
| Q38573785 | Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? |
| Q37964916 | Treatment of relapsed or refractory chronic lymphocytic leukemia |